Astellas Pharma 4503.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
2,582.5
+4.49%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Astellas Pharma
Its shares trade on Tokyo Stock Exchange under the ticker 4503.T. It has been listed since 16 May 1949. In the fiscal year to 31 March 2026, it reported revenue of ¥2.14trn and net income of ¥291.54bn. At that date it held total assets of ¥3.57trn and shareholders' equity of ¥1.83trn.
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 May 1949
- Employees
- 15,883
- Website
- astellas.com/jp ↗
Leadership
Pay as last reported
- Mr. Kenji YasukawaChairman of the Board, Chairman of the Board of Directors, Representative Director¥309.0m
- Mr. Naoki OkamuraPresident, Chief Executive Officer, Representative Director, since 2016¥461.0m
- Mr. Atsushi KitamuraChief Financial Officer, Senior Managing Executive Officer
- Dr. Yoshitsugu ShitakaSenior Managing Executive Officer, Chief Scientific Officer
- Mr. Katsuyoshi SugitaVice President, Chief People Officer, Chief Ethics & Compliance Officer, Manager of Human Resource Division, Representative Director, since 2022¥179.0m
- Ms. Catherine LevittGeneral Counsel
- Mr. Hideki ShimaSenior Managing Executive Officer, Chief Manufacturing Officer
- Dr. Tadaaki TaniguchiSenior Managing Executive Officer, Chief Medical Officer
- Mr. Jun KonoManaging Executive Officer, Head of Japan Commercial
- Mr. Yuusuke KumagaiExecutive Officer, Director of External Affairs
- Mr. Eisuke NozawaExecutive Officer, Director of Pharmaceutical Affairs
- Mr. Nick EshkenaziChief Digital & Transformation Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 95
- Environment
- 99
- Social
- 99
- Governance
- 86
- Direct emissions (scope 1)
- 59,203 t
- Energy emissions (scope 2)
- 63,047 t
- Value chain emissions (scope 3)
- 1,121,350 t
- Women in the workforce
- 47.51%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Astellas Pharma Inc has built a strong brand reputation in the pharmaceutical industry through its high-quality products, ethical business practices, and commitment to innovation.
- The company offers a diverse range of pharmaceutical products across multiple therapeutic areas, providing a competitive advantage and reducing dependence on a single product or market.
- Astellas Pharma Inc has a global presence with operations in multiple countries, allowing the company to capitalize on international market opportunities and reach a larger customer base.
- The company invests significantly in research and development, fostering innovation and enabling the development of novel drugs and treatments that address unmet medical needs.
Weaknesses
- Astellas Pharma Inc relies heavily on a few key products for a significant portion of its revenue, making the company vulnerable to potential declines in sales if these products face competition or patent expiration.
- The pharmaceutical industry is subject to strict regulations and compliance requirements, and changes in regulations or unexpected challenges in obtaining regulatory approvals can impact the company's product pipeline and business operations.
Opportunities
- Astellas Pharma Inc can expand its market presence by targeting emerging markets, where growing populations, increasing healthcare spending, and rising awareness of healthcare contribute to significant growth opportunities.
- The company can explore opportunities in the field of biotechnology, which offers potential for the development of innovative therapies and treatments that align with changing medical needs and technological advancements.
Threats
- Astellas Pharma Inc operates in a highly competitive industry, facing competition from other pharmaceutical companies, generic drug manufacturers, and new entrants, which can impact market share and pricing.
- The company's intellectual property rights may be challenged or infringed upon by competitors, affecting market exclusivity and potentially leading to revenue loss.
- Government interventions such as price controls and healthcare reforms can impact the pricing and reimbursement of pharmaceutical products, posing financial challenges and potentially affecting profitability for Astellas Pharma Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.